Nonetheless, the curves bear some resemblance to the hypothetical model in Jack et al. (2010), with the earliest phase of preclinical disease showing dynamic molecular pathology (CSF p-tau, and PiB-PET), and other biomarkers becoming dynamic as onset approaches: global cognitive decline (MMSE), neurodegeneration (MRI volumes), and hypometabolism (FDG-PET). The gene discussed is MAPT; the disease is Mental deterioration.